InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.720 0.005 (0.70%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$196 OCC Secures Access to 221 U.S. Military Medical Centres 15 Apr 2026 9:00AM $0.870 $0.720 fallen by 17.24%
$196 Notification of cessation of securities - OCC 15 Apr 2026 8:25AM $0.870 $0.720 fallen by 17.24%
$196 Orthocell Investor Webinar Details 14 Apr 2026 10:20AM $0.865 $0.720 fallen by 16.76%
$196 US Section 232 Tariffs Not Expected to Affect Remplir 8 Apr 2026 9:06AM $0.760 $0.720 fallen by 5.26%
$196 Orthocell Investor Presentation - Broker Meets Biotech 31 Mar 2026 2:43PM $0.765 $0.720 fallen by 5.88%
$196 Remplir Used in 23 Surgeries in Ukrainian soldiers 18 Mar 2026 9:57AM $0.780 $0.720 fallen by 7.69%
$196 Notification of cessation of securities - OCC 16 Mar 2026 7:29PM $0.785 $0.720 fallen by 8.28%
$196 Notification regarding unquoted securities - OCC 16 Mar 2026 6:34PM $0.785 $0.720 fallen by 8.28%
$196 Orthocell Appoints UK Distributor for Remplir 10 Mar 2026 9:08AM $0.800 $0.720 fallen by 10%
$196 Appendix 3Y - Michael McNulty 26 Feb 2026 8:47AM $0.955 $0.720 fallen by 24.61%
$196 Appendix 3Y - John Van Der Wielen 26 Feb 2026 8:46AM $0.955 $0.720 fallen by 24.61%
$196 Appendix 4D & Half-Year Financial Report 24 Feb 2026 9:02AM $0.900 $0.720 fallen by 20%
$196 Orthocell Receives $3.0m R&D Tax Refund 18 Feb 2026 12:56PM $0.930 $0.720 fallen by 22.58%
$196 US Market and Operational Update 2 Feb 2026 9:02AM $0.920 $0.720 fallen by 21.74%
$196 Orthocell Investor Webinar Details 29 Jan 2026 10:21AM $0.870 $0.720 fallen by 17.24%
$196 Quarterly Activity Report & Appendix 4C 19 Jan 2026 9:07AM $1.000 $0.720 fallen by 28%
$196 Orthocell Finalises Strategic Investment in Marine Biomedica 16 Jan 2026 9:01AM $1.015 $0.720 fallen by 29.06%
$196 Orthocell Posts Seventh Straight Record Revenue Quarter 6 Jan 2026 9:33AM $1.095 $0.720 fallen by 34.25%
$196 Appendix 3Y - Paul Anderson 22 Dec 2025 6:10PM $1.045 $0.720 fallen by 31.10%
$196 Cleansing Notice 22 Dec 2025 6:06PM $1.045 $0.720 fallen by 31.10%
$196 Application for quotation of securities - OCC 22 Dec 2025 6:04PM $1.045 $0.720 fallen by 31.10%
$196 Orthocell Hits US Milestone - 100 Remplir Units Sold. 18 Dec 2025 9:42AM $1.025 $0.720 fallen by 29.76%
$196 Remplir Regulatory Application for US$750m EU-UK Market 15 Dec 2025 9:05AM $1.020 $0.720 fallen by 29.41%
$196 First Commercial Sales of Remplir Achieved in Hong Kong 10 Dec 2025 9:18AM $1.015 $0.720 fallen by 29.06%
$196 Appendix 3Y - Paul Anderson 28 Nov 2025 6:28PM $1.070 $0.720 fallen by 32.71%

26 - 50 of 759 results

Page 2 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.